AUM Biosciences

Founded by 2 ex-Quintiles (Now IQVIA) and industry veterans, AUM Biosciences is an oncology-focused biotechnology company headquartered in Singapore that develops innovative and affordable medicines for patients in Asia and globally.

The founders and the management team have over 75 years of combined oncology drug development experience, and track record of developing and executing various virtual drug development models in the Industry. AUM’s pipeline includes a novel, small molecule targeted therapy which has the potential to address high unmet medical needs in various solid and liquid tumours. Additionally, it has an undisclosed pipeline of additional pre-clinical and phase I ready programs. Pipeline focus is on small molecules targeted therapies with a mandate of clear biomarker driven strategies for every asset in the pipeline. AUM harnesses the power of precision medicine and digital technologies to accelerate the drug development timelines to unlock the value of innovation.